St. Jude Vascular Closure Business Continues To Top 50% Sales Growth
This article was originally published in The Gray Sheet
Executive Summary
Widespread acceptance of femoral artery closure devices pushed second-quarter sales of St. Jude Medical's Angio-Seal vascular closure device 52% versus the year-ago period, driving the firm's overall second-quarter earnings by almost 12% to $336 mil.
You may also be interested in...
CardioFocus Lightstic Ablation Laser Signals Valve Market Growth - Edwards
Edwards Lifesciences will promote CardioFocus' Lightstic device for the treatment of cardiac arrhythmias in cardiac valve repair patients, backed by data from a one-year clinical study of the diode ablation laser.
CardioFocus Lightstic Ablation Laser Signals Valve Market Growth - Edwards
Edwards Lifesciences will promote CardioFocus' Lightstic device for the treatment of cardiac arrhythmias in cardiac valve repair patients, backed by data from a one-year clinical study of the diode ablation laser.
St. Jude
Second-quarter sales advanced 11.7% to $336.1 mil., generating net earnings of $43.8 mil., up 28.4% (1"The Gray Sheet" July 23, 2001, p. 9). The company notes a total market opportunity of $250 mil. for vascular connectors used in cardiac bypass